Latest news and press releases about MDxHealth S.A. (MDXH): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool.
Price
| Price | $0.68 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | BE |
Valuation Ratios
| Price / Book | -2.92 |
| EV / EBITDA | -17.51 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 402.97% |
| Return on Invested Capital | -12.74% |
| Return on Assets | -17.67% |
| Gross Margin | 57.68% |
| Operating Margin | -16.59% |
| Net Margin | -32.17% |
Related companies: ACRS · ASMB · IMRX · NEO · QTRX · SI · SNWV
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of MDXH: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks